Tisagenlecleucel
- Generic Name
- Tisagenlecleucel
- Brand Names
- Kymriah
- Drug Type
- Biotech
- CAS Number
- 1823078-37-0
- Unique Ingredient Identifier
- Q6C9WHR03O
Overview
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Background
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Indication
Tisagenlecleucel is indicated for use in individuals aged 25 years and younger with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. It is also used to treat adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Tisagenlecleucel is also indicated in adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Associated Conditions
- Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Refractory Follicular Lymphoma
- Relapsed Diffuse Large B-cell Lymphoma (DLBCL)
- Relapsed Follicular Lymphoma
- Refractory B-cell precursor acute lymphoblastic leukemia
- Relapsed B cell precursor Acute lymphoblastic leukemia
Clinical Trials
Login Required
To view more clinical trials, please log in to your account.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2018/08/22 | Phase 2 | Active, not recruiting | |||
2018/07/26 | N/A | AVAILABLE | |||
2018/06/27 | Phase 3 | Active, not recruiting | |||
2018/06/26 | Phase 2 | Active, not recruiting | |||
2014/06/19 | Phase 2 | Withdrawn |
FDA Approved Products
Login Required
To view more FDA approved products, please log in to your account.
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|
No FDA products found
No FDA products found for this drug
EMA Approved Products
Login Required
To view more EMA approved products, please log in to your account.
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
Singapore Approved Products
Login Required
To view more Singapore approved products, please log in to your account.
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. |
|---|
No Singapore products found
No Singapore products found for this drug
China Approved Products
Login Required
To view more China approved products, please log in to your account.
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|
No China products found
No China products found for this drug
Australia Approved Products
Login Required
To view more Australia approved products, please log in to your account.
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|
No Australia products found
No Australia products found for this drug